Biogen first-quarter profit jumps 71 percent as MS drug Tecfidera shines
April 24, 2015 at 07:10 AM EDT
(Reuters) - Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis (MS) drug, Tecfidera.